Journal article · 2025 · Open access
Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial
The Lancet Oncology, 26(12), 1651–1664 · Published 25 November 2025 · DOI 10.1016/s1470-2045(25)00492-9
In brief
“Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial” is a 2025 journal article by Graeme F. Woodworth and 38 co-authors, published in The Lancet Oncology. OpenAlex counts 71 citations as of 17 November 2026, which puts it in the top 7% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at The Lancet Oncology.
- Citations
- 71
- Most cited in
- 2026 (69)
- Field-weighted impact
- 13.05
- References
- 31
- Authors
- 39
Abstract
BACKGROUND: Brain-infiltrating tumour cells from high-grade glioma remain shielded from drug treatments by the blood-brain barrier, leading to inevitable recurrence. Microbubble-enhanced transcranial focused ultrasound (MB-FUS) enables controlled blood-brain barrier opening (BBBO), permitting localised drug delivery. We aimed to assess safety and feasibility of MB-FUS plus standard-of-care chemotherapy for individuals with high-grade glioma. METHODS: of body surface area). MRI-guided, 220 kHz transcranial MB-FUS treatments were delivered in periresectional (tumour-infiltrative) regions, on any of the first 3 days of a 28-day temozolomide cycle, for up to six cycles. Primary outcomes were safety (adverse events) and feasibility (BBBO: new contrast enhancement on post-procedure T1-weighted MRI). Protocol-prespecified secondary outcomes were overall survival and progression-free survival. Analyses were done in the intention-to-treat population. This trial is registered at ClinicalTrials.gov, NCT03551249 (USA) and NCT03616860 (Canada), and is closed to enrolment. FINDINGS: Between Oct 16, 2018, and March 9, 2022, we enrolled 34 participants, all evaluable for prespecified primary and secondary endpoints, with a mean age of 51·5 years (SD 13·0) and median follow-up 44·5 months (95% CI 34·9-57·3). By self-reporting, 18 (53%) participants were female and 16 (47%) male, 28 (82%) were White, and 34 (100%) were non-Hispanic. 176 adverse events were captured: 54 (31%) chemotherapy-related, 10 (6%) disease-related, 87 (49%) related to undergoing MB-FUS (40 [46%] grade 1, 46 [53%] grade 2, and one [1%] grade 3), and 25 (14%) unrelated. Two (1%) of the adverse events were grade 5 (disease-related deaths), three (2%) grade 4 (temozolomide-related haematological abnormalities), and eight (5%) grade 3 (three [2%] temozolomide-related, one [1%] MB-FUS-related, three [2%] disease-related, and one [1%] unrelated); these occurred across seven (21%) of 34 participants. No treatment-related deaths occurred during the trial. BBBO was visualised in all treatments. Median overall survival was 31·3 months (95% CI 21·1-not reached) and median progression-free survival was 13·5 months (9·9-26·9) with patient-specific disease courses found concordant with trajectories of MB-FUS-enriched plasma cell-free DNA. INTERPRETATION: MB-FUS plus temozolomide is a safe combinatorial therapeutic approach for individuals with high-grade glioma, with the potential to improve survival and enable non-invasive plasma biomarker-based disease surveillance (sono-liquid biopsy), warranting randomised controlled trials. FUNDING: National Institutes of Health and Insightec.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Woodworth, G. F., Anastasiadis, P., Ozair, A., Chabros, J., Bettegowda, C., Chen, C., Gerstl, J. V. E., Douville, C. B., Mekary, R. A., Smith, T. R., Meng, Y., Hawkins, C. E., Pople, C. B., Abrahão, A., Llinas, M., Heyn, C., Bunevičius, A., Rezai, A. R., Ball, A., . . . Lipsman, N. (2025). Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial. The Lancet Oncology, 26(12), 1651–1664. https://doi.org/10.1016/s1470-2045(25)00492-9
MLA 9
Woodworth, Graeme F., et al. “Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial.” The Lancet Oncology, vol. 26, no. 12, 2025, pp. 1651–1664. https://doi.org/10.1016/s1470-2045(25)00492-9.
Chicago
Woodworth, Graeme F., Pavlos Anastasiadis, Ahmad Ozair, Jeremi Chabros, Chetan Bettegowda, Chixiang Chen, Jakob V. E. Gerstl, et al. 2025. “Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial.” The Lancet Oncology 26 (12): 1651–1664. https://doi.org/10.1016/s1470-2045(25)00492-9.
Harvard
Woodworth, G. F. et al. (2025) ‘Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial’, The Lancet Oncology, 26(12), pp. 1651–1664. doi:10.1016/s1470-2045(25)00492-9.
IEEE
G. F. Woodworth et al., “Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial,” The Lancet Oncology, vol. 26, no. 12, pp. 1651–1664, 2025, doi: 10.1016/s1470-2045(25)00492-9.
BibTeX
@article{woodworth2025microbubble,
title = {{Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial}},
author = {Woodworth, Graeme F. and Anastasiadis, Pavlos and Ozair, Ahmad and Chabros, Jeremi and Bettegowda, Chetan and Chen, Chixiang and Gerstl, Jakob V. E. and Douville, Christopher Blair and Mekary, Rania A. and Smith, Timothy Ryan and Meng, Ying and Hawkins, Cynthia E and Pople, Christopher B. and Abrahão, Agessandro and Llinas, Maheleth and Heyn, Chris and Bunevičius, Adomas and Rezai, Ali R. and Ball, Anna and Henry, Kaitlyn and Sahgal, Arjun and Torio, Erickson and Ren, Haoyu and Ahmad, Haroon and Arora, Harshit and Eisenberg, Howard M. and Perry, James and Carpenter, Jeffrey and Hynynen, Kullervo and Pham, Lily C and others},
journal = {The Lancet Oncology},
year = {2025},
volume = {26},
number = {12},
pages = {1651--1664},
doi = {10.1016/s1470-2045(25)00492-9},
url = {https://doi.org/10.1016/s1470-2045(25)00492-9}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- transcranial focused ultrasound
- microbubbles
- temozolomide
- high-grade glioma
- blood-brain barrier opening
- peritumoral infiltration
- MRI-guided ultrasound
- treatment safety and feasibility
Work with this paper
Most-cited papers in Engineering
- A Closed‐form Equation for Predicting the Hydraulic Conductivity of Unsaturated SoilsMartinus Th. van Genuchten · Soil Science Society of America Journal · 1980 · 28,197 citations
- An improved technique for determining hardness and elastic modulus using load and displacement sensing indentation experimentsW. C. Oliver, George M. Pharr · Journal of materials research/Pratt's guide to venture capital sources · 1992 · 27,379 citations
- Digital communicationsOwen Bishop · Routledge eBooks · 2007 · 24,890 citations
- The empirical mode decomposition and the Hilbert spectrum for nonlinear and non-stationary time series analysisNorden Eh Huang, Zhengwei Shen, Steven R. Long and 6 more · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · 1998 · 24,008 citations
- Numerical Heat Transfer and Fluid FlowSuhas V. Patankar · CRC Press eBooks · 2018 · 23,491 citations
Questions about this paper
How do I cite this paper in APA style?
Woodworth, G. F., Anastasiadis, P., Ozair, A., Chabros, J., Bettegowda, C., Chen, C., Gerstl, J. V. E., Douville, C. B., Mekary, R. A., Smith, T. R., Meng, Y., Hawkins, C. E., Pople, C. B., Abrahão, A., Llinas, M., Heyn, C., Bunevičius, A., Rezai, A. R., Ball, A., . . . Lipsman, N. (2025). Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial. The Lancet Oncology, 26(12), 1651–1664. https://doi.org/10.1016/s1470-2045(25)00492-9
How many times has this paper been cited?
71 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at The Lancet Oncology: sign in and open the full text from this page.
Who wrote this paper?
Graeme F. Woodworth, Pavlos Anastasiadis, Ahmad Ozair, Jeremi Chabros, Chetan Bettegowda, Chixiang Chen, Jakob V. E. Gerstl, Christopher Blair Douville, Rania A. Mekary, Timothy Ryan Smith, Ying Meng, Cynthia E Hawkins and 27 more.
What is the DOI of this paper?
10.1016/s1470-2045(25)00492-9, permanently at https://doi.org/10.1016/s1470-2045(25)00492-9. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.